{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:05:56Z","timestamp":1792857956359,"version":"4.5.0"},"reference-count":122,"publisher":"Georg Thieme Verlag KG","issue":"03","funder":[{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["FONDECYT 1200227 to JPA and 1241450 to MA"],"award-info":[{"award-number":["FONDECYT 1200227 to JPA and 1241450 to MA"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>The new nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasizes a positive diagnosis based on cardiometabolic risk factors. This definition is not only less stigmatizing but also allows for subclassification and stratification, thereby addressing the heterogeneity of what was historically referred to as nonalcoholic fatty liver disease. The heterogeneity within this spectrum is influenced by several factors which include but are not limited to demographic\/dietary factors, the amount of alcohol use and drinking patterns, metabolic status, gut microbiome, genetic predisposition together with epigenetic factors. The net effect of this dynamic and intricate system-level interaction is reflected in the phenotypic presentation of MASLD. Therefore, the application of precision medicine in this scenario aims at complex phenotyping with consequent individual risk prediction, development of individualized preventive strategies, and improvements in the clinical trial designs. In this review, we aim to highlight the importance of precision medicine approaches in MASLD, including the use of novel biomarkers of disease, and its subsequent utilization in future study designs.<\/jats:p>","DOI":"10.1055\/a-2364-2928","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T22:58:07Z","timestamp":1720738687000},"page":"273-286","source":"Crossref","is-referenced-by-count":14,"title":["A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD"],"prefix":"10.1055","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4968-4066","authenticated-orcid":false,"given":"Nimish","family":"Thakral","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Kentucky, Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2042-5797","authenticated-orcid":false,"given":"Hailemichael","family":"Desalegn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-4930","authenticated-orcid":false,"given":"Luis Antonio","family":"Diaz","sequence":"additional","affiliation":[{"name":"Departamento de Gastroenterolog\u00eda, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-725X","authenticated-orcid":false,"given":"Daniel","family":"Cabrera","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica (CiiB), Universidad de los Andes, Santiago, Chile"},{"name":"Escuela de Medicina, Facultad de Ciencias Medicas, Universidad Bernardo O'Higgins, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, MASLD Research Center, University of California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0499-4191","authenticated-orcid":false,"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[{"name":"Departamento de Gastroenterolog\u00eda, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-396X","authenticated-orcid":false,"given":"Juan Pablo","family":"Arab","sequence":"additional","affiliation":[{"name":"Departamento de Gastroenterolog\u00eda, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"issue":"04","key":"ref1","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"G Targher","year":"2024","journal-title":"Gut"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Z M Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"H Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach","volume":"28","author":"M H Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/liv.15852","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa","volume":"44","author":"Z M Younossi","year":"2024","journal-title":"Liver Int"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"M E Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"V Ratziu","year":"2024","journal-title":"J Hepatol"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/advances\/nmaa081","article-title":"Animal models of fibrosis in nonalcoholic steatohepatitis: do they reflect human disease?","volume":"11","author":"D H Ipsen","year":"2020","journal-title":"Adv Nutr"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"nzab138","DOI":"10.1093\/cdn\/nzab138","article-title":"Considerations when choosing high-fat, high-fructose, and high-cholesterol diets to induce experimental nonalcoholic fatty liver disease in laboratory animal models","volume":"5","author":"S Radhakrishnan","year":"2021","journal-title":"Curr Dev Nutr"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jceh.2019.03.002","article-title":"Drug development for nonalcoholic fatty liver disease: landscape and challenges","volume":"9","author":"P Thiagarajan","year":"2019","journal-title":"J Clin Exp Hepatol"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"M Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1112159","DOI":"10.3389\/fsoc.2023.1112159","article-title":"Precision and personalized medicine: what their current definition says and silences about the model of health they promote. Implication for the development of personalized health","volume":"8","author":"C Delpierre","year":"2023","journal-title":"Front Sociol"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"E Tr\u00e9po","year":"2020","journal-title":"J Hepatol"},{"issue":"07","key":"ref15","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond","volume":"158","author":"M Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12902-021-00789-4","article-title":"Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"N Salari","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"13","key":"ref17","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1016\/j.cgh.2023.04.024","article-title":"Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease","volume":"21","author":"C Rosso","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2014.10.048","article-title":"HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance","volume":"62","author":"M Krawczyk","year":"2015","journal-title":"J Hepatol"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.4254\/wjh.v13.i11.1584","article-title":"Heterogeneity of non-alcoholic fatty liver disease: implications for clinical practice and research activity","volume":"13","author":"P Pal","year":"2021","journal-title":"World J Hepatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.atherosclerosis.2017.01.008","article-title":"\u201cNot all forms of NAFLD were created equal\u201d. Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?","volume":"257","author":"A Lonardo","year":"2017","journal-title":"Atherosclerosis"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3350\/cmh.2020.0136","article-title":"Precision medicine in nonalcoholic fatty liver disease: new therapeutic insights from genetics and systems biology","volume":"26","author":"S Sookoian","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1053\/j.gastro.2020.12.011","article-title":"Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study","volume":"160","author":"C A Emdin","year":"2021","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3878807\/v1","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","author":"S Romeo","year":"2024","journal-title":"Res Sq"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis","volume":"19","author":"M Balakrishnan","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jcsm.12598","article-title":"Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey","volume":"11","author":"S Kang","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/liv.14719","article-title":"Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"41","author":"Y C Hsieh","year":"2021","journal-title":"Liver Int"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"C Caussy","year":"2019","journal-title":"Nat Commun"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"R Loomba","year":"2017","journal-title":"Cell Metab"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MEG.0000000000001541","article-title":"Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"32","author":"K Wijarnpreecha","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"32002","DOI":"10.1038\/srep32002","article-title":"Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease","volume":"6","author":"B Wang","year":"2016","journal-title":"Sci Rep"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"G Lee","year":"2020","journal-title":"Nat Commun"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","article-title":"Intestinal virome signature associated with severity of nonalcoholic fatty liver disease","volume":"159","author":"S Lang","year":"2020","journal-title":"Gastroenterology"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"A L Hutchison","year":"2023","journal-title":"J Hepatol"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","article-title":"Perspectives on precision medicine approaches to NAFLD diagnosis and management","volume":"38","author":"A Lonardo","year":"2021","journal-title":"Adv Ther"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/cen.13440","article-title":"Prevalence of treated hypothyroidism in the community: analysis from general practices in North-East England with implications for the United Kingdom","volume":"87","author":"L Ingoe","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1262-3636(07)70147-7","article-title":"Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms","volume":"30","author":"A J Scheen","year":"2004","journal-title":"Diabetes Metab"},{"issue":"S 02","key":"ref39","first-page":"12","article-title":"The phenotype of adults with partial growth hormone deficiency","volume":"64","author":"R D Murray","year":"2005","journal-title":"Horm Res"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2337\/diacare.28.1.120","article-title":"Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance","volume":"28","author":"G Sesti","year":"2005","journal-title":"Diabetes Care"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0026-0495(99)90077-X","article-title":"Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy","volume":"48","author":"F J Hayes","year":"1999","journal-title":"Metabolism"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-133-2-200007180-00010","article-title":"Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial","volume":"133","author":"G Sesmilo","year":"2000","journal-title":"Ann Intern Med"},{"issue":"05","key":"ref43","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdi.13268","article-title":"Increased risks of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7-6.4% in a Chinese population","volume":"11","author":"C H Li","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.coph.2012.02.008","article-title":"Oestrogen's regulation of fat metabolism during exercise and gender specific effects","volume":"12","author":"T Oosthuyse","year":"2012","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/cells8101259","article-title":"Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"8","author":"C Lee","year":"2019","journal-title":"Cells"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.mayocp.2013.11.011","article-title":"A pooled analysis of waist circumference and mortality in 650,000 adults","volume":"89","author":"J R Cerhan","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/1471-2458-12-631","article-title":"Waist circumference a good indicator of future risk for type 2 diabetes and cardiovascular disease","volume":"12","author":"R Siren","year":"2012","journal-title":"BMC Public Health"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"R Loomba","year":"2018","journal-title":"Gastroenterology"},{"issue":"66","key":"ref49","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0168-8278(17)30328-8","article-title":"Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH","volume":"1","author":"E Lawitz","year":"2017","journal-title":"J Hepatol"},{"issue":"10","key":"ref50","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"V Ratziu","year":"2021","journal-title":"Nat Med"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"R Loomba","year":"2021","journal-title":"Gastroenterology"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"B A Davison","year":"2020","journal-title":"J Hepatol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"G Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"issue":"07","key":"ref54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"J H Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"ref55","first-page":"270","article-title":"Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes","volume":"37","author":"H Fennoun","year":"2020","journal-title":"Pan Afr Med J"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-5926-4-10","article-title":"The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis","volume":"4","author":"T Poynard","year":"2005","journal-title":"Comp Hepatol"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"R Hernaez","year":"2011","journal-title":"Hepatology"},{"issue":"05","key":"ref58","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2017.01.029","article-title":"Detecting liver fat from viscoelasticity: how good is CAP in clinical practice? The need for universal cut-offs","volume":"66","author":"M Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"issue":"11","key":"ref59","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3748\/wjg.v25.i11.1307","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice","volume":"25","author":"J H Zhou","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2893.2006.00811.x","article-title":"Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases","volume":"14","author":"B Coco","year":"2007","journal-title":"J Viral Hepat"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/hep.22577","article-title":"Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis","volume":"48","author":"G Millonig","year":"2008","journal-title":"Hepatology"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"C Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref63","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"K Imajo","year":"2016","journal-title":"Gastroenterology"},{"issue":"03","key":"ref64","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"C C Park","year":"2017","journal-title":"Gastroenterology"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cca.2012.04.019","article-title":"Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease","volume":"413","author":"Y Yilmaz","year":"2012","journal-title":"Clin Chim Acta"},{"issue":"02","key":"ref66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11306-020-01756-1","article-title":"Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis","volume":"17","author":"M Masarone","year":"2021","journal-title":"Metabolomics"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease","volume":"60","author":"S C Kalhan","year":"2011","journal-title":"Metabolism"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1194\/jlr.D800028-JLR200","article-title":"Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry","volume":"50","author":"P Wiesner","year":"2009","journal-title":"J Lipid Res"},{"issue":"04","key":"ref69","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/prca.200900119","article-title":"Non-alcoholic fatty liver disease proteomics","volume":"4","author":"E Rodr\u00edguez-Su\u00e1rez","year":"2010","journal-title":"Proteomics Clin Appl"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease\u2013the role of transient elastography and plasma cytokeratin-18 fragments","volume":"39","author":"R Kwok","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"31","key":"ref71","doi-asserted-by":"crossref","first-page":"10851","DOI":"10.3748\/wjg.v20.i31.10851","article-title":"Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future","volume":"20","author":"E Fitzpatrick","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.28776","article-title":"Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease","volume":"65","author":"V Ajmera","year":"2017","journal-title":"Hepatology"},{"issue":"10","key":"ref73","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1194\/jlr.M007096","article-title":"Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"51","author":"A E Feldstein","year":"2010","journal-title":"J Lipid Res"},{"issue":"07","key":"ref74","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s10620-014-3031-8","article-title":"OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease","volume":"59","author":"N Alkhouri","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"D L Gorden","year":"2015","journal-title":"J Lipid Res"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/gut.2009.176651","article-title":"Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease","volume":"59","author":"T Asanuma","year":"2010","journal-title":"Gut"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1148\/radiol.2015150952","article-title":"Noninvasive differentiation between hepatic steatosis and steatohepatitis with MR imaging enhanced with USPIOs in patients with nonalcoholic fatty liver disease: a proof-of-concept study","volume":"278","author":"L P Smits","year":"2016","journal-title":"Radiology"},{"issue":"03","key":"ref78","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1148\/radiol.14131890","article-title":"Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study","volume":"271","author":"N Bastati","year":"2014","journal-title":"Radiology"},{"issue":"11","key":"ref79","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"J G Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","article-title":"Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease","volume":"71","author":"N Tamaki","year":"2022","journal-title":"Gut"},{"issue":"02","key":"ref81","first-page":"103","article-title":"Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease","volume":"11","author":"Y Yilmaz","year":"2011","journal-title":"Hepat Mon"},{"issue":"06","key":"ref82","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"R K Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"08","key":"ref83","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"G Musso","year":"2011","journal-title":"Ann Med"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cgh.2019.05.051","article-title":"Development and validation of Hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis","volume":"18","author":"J Ampuero","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"ref85","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1007\/s10620-020-06821-2","article-title":"Hepamet fibrosis score in nonalcoholic fatty liver disease patients in Mexico: lower than expected positive predictive value","volume":"66","author":"F Higuera-de-la-Tijera","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"11","key":"ref86","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3390\/jcm10112415","article-title":"FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis","volume":"10","author":"Y Vali","year":"2021","journal-title":"J Clin Med"},{"issue":"02","key":"ref87","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers","volume":"47","author":"I N Guha","year":"2008","journal-title":"Hepatology"},{"issue":"01","key":"ref88","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.gastro.2008.09.013","article-title":"Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease","volume":"136","author":"V Nobili","year":"2009","journal-title":"Gastroenterology"},{"issue":"02","key":"ref89","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Y Vali","year":"2020","journal-title":"J Hepatol"},{"issue":"10","key":"ref90","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/j.1440-1746.2011.06774.x","article-title":"Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease","volume":"26","author":"L A Adams","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"06","key":"ref91","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s10620-023-07896-3","article-title":"Comparative accuracy of clinical fibrosis markers, Hepascore and Fibroscan\u00ae to detect advanced fibrosis in patients with nonalcoholic fatty liver disease","volume":"68","author":"L C Bertot","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"11","key":"ref92","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"S A Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"ref93","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","article-title":"Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis","volume":"29","author":"A J Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"ref94","first-page":"107","article-title":"The clinical utility of FibroScan(\u00ae) as a noninvasive diagnostic test for liver disease","volume":"7","author":"J Wilder","year":"2014","journal-title":"Med Devices (Auckl)"},{"issue":"05","key":"ref95","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"G Xiao","year":"2017","journal-title":"Hepatology"},{"issue":"05","key":"ref96","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.diii.2013.02.005","article-title":"Ultrasound elastography in liver","volume":"94","author":"N Frulio","year":"2013","journal-title":"Diagn Interv Imaging"},{"issue":"01","key":"ref97","doi-asserted-by":"crossref","first-page":"W20","DOI":"10.2214\/AJR.19.21267","article-title":"Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease","volume":"214","author":"A Furlan","year":"2020","journal-title":"AJR Am J Roentgenol"},{"issue":"06","key":"ref98","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/hep.25936","article-title":"Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study","volume":"56","author":"G Ferraioli","year":"2012","journal-title":"Hepatology"},{"issue":"06","key":"ref99","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.27362","article-title":"Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study","volume":"60","author":"R Loomba","year":"2014","journal-title":"Hepatology"},{"issue":"05","key":"ref100","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"M E Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"03","key":"ref101","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cgh.2014.09.046","article-title":"Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data","volume":"13","author":"S Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmri.24084","article-title":"Magnetic resonance elastography of liver in healthy Asians: normal liver stiffness quantification and reproducibility assessment","volume":"39","author":"S K Venkatesh","year":"2014","journal-title":"J Magn Reson Imaging"},{"issue":"04","key":"ref103","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"J J Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"issue":"10","key":"ref104","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"70","author":"J Jung","year":"2021","journal-title":"Gut"},{"issue":"06","key":"ref105","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","article-title":"Impact of non-invasive biomarkers on hepatology practice: past, present and future","volume":"76","author":"Q M Anstee","year":"2022","journal-title":"J Hepatol"},{"issue":"05","key":"ref106","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/liv.12584","article-title":"The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"35","author":"S Petta","year":"2015","journal-title":"Liver Int"},{"issue":"07","key":"ref107","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/jgh.13671","article-title":"Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease","volume":"32","author":"T CW Loong","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"05","key":"ref108","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR Trials","volume":"70","author":"Q M Anstee","year":"2019","journal-title":"Hepatology"},{"issue":"06","key":"ref109","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/hepr.13495","article-title":"Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"50","author":"C Inadomi","year":"2020","journal-title":"Hepatol Res"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00535-019-01626-1","article-title":"Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease","volume":"55","author":"T Shima","year":"2020","journal-title":"J Gastroenterol"},{"issue":"06","key":"ref111","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/hep.31655","article-title":"Transient versus two-dimensional shear-wave elastography in a multistep strategy to detect advanced fibrosis in NAFLD","volume":"73","author":"C Cassinotto","year":"2021","journal-title":"Hepatology"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2013.05.021","article-title":"Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver","volume":"424","author":"H Yamada","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"03","key":"ref113","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/2211536607666180531093302","article-title":"Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD)","volume":"7","author":"K Jampoka","year":"2018","journal-title":"MicroRNA"},{"issue":"10","key":"ref114","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2019.190335","article-title":"Decreased serum miR-1296 may serve as an early biomarker for the diagnosis of non-alcoholic fatty liver disease","volume":"65","author":"F Yu","year":"2019","journal-title":"Clin Lab"},{"issue":"01","key":"ref115","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3892\/mmr.2021.12137","article-title":"Circulating microRNA\u2013135a\u20133p in serum extracellular vesicles as a potential biological marker of non\u2013alcoholic fatty liver disease","volume":"24","author":"H Jiang","year":"2021","journal-title":"Mol Med Rep"},{"issue":"08","key":"ref116","doi-asserted-by":"crossref","first-page":"e23937","DOI":"10.1371\/journal.pone.0023937","article-title":"Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease","volume":"6","author":"S Cermelli","year":"2011","journal-title":"PLoS One"},{"issue":"05","key":"ref117","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"C J Pirola","year":"2015","journal-title":"Gut"},{"issue":"44","key":"ref118","doi-asserted-by":"crossref","first-page":"9844","DOI":"10.3748\/wjg.v22.i44.9844","article-title":"Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population","volume":"22","author":"X L Liu","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"01","key":"ref119","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1038\/s41598-018-28854-4","article-title":"Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers","volume":"8","author":"M L\u00f3pez-Riera","year":"2018","journal-title":"Sci Rep"},{"issue":"05","key":"ref120","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Z M Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"05","key":"ref121","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/lt.25443","article-title":"NASH is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the United States: a population-based study","volume":"25","author":"P Axley","year":"2019","journal-title":"Liver Transpl"},{"issue":"04","key":"ref122","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/SLA.0b013e31826b4b7e","article-title":"Liver transplantation for nonalcoholic steatohepatitis: the new epidemic","volume":"256","author":"V G Agopian","year":"2012","journal-title":"Ann Surg"},{"issue":"08","key":"ref123","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"V WS Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"06","key":"ref124","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2020.08.014","article-title":"Liver biopsy reliability in clinical trials: thoughts from a liver pathologist","volume":"73","author":"E M Brunt","year":"2020","journal-title":"J Hepatol"},{"issue":"05","key":"ref125","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2022.01.011","article-title":"Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD","volume":"76","author":"E M Brunt","year":"2022","journal-title":"J Hepatol"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2364-2928.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:15:31Z","timestamp":1730823331000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2364-2928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":122,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,10,3]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2364-2928","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7,11]]},"published":{"date-parts":[[2024,7,11]]}}}